Repare Therapeutics Inc

Repare Therapeutics — Investor Presentation (October 2023)

33 slides from Repare Therapeutics's investor presentation, Oct 13, 2023

  1. Slide 1: Corporate Presentation October 2023

    Insight that enriches. Precision that empowers. Corporate Presentation October 2023 Exhibit 99.2

  2. Slide 2: Disclaimer

    Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “poten

  3. Slide 3: Developing Next-Generation Precision Oncology Therapeutics

    Differentiated and expanding clinical-stage pipeline Lunresertib: First-in-class oral PKMYT1 inhibitor (Phase 1/2) Camonsertib: ATR inhibitor (Partnered with Roche) Additional near-term clinical programs Potential across multiple tumor types Proprietary CRISPR-enabled SNIPRx platform Focused on geno

  4. Slide 4: Targeting the un-targetable through synthetic lethality

    Targeting the un-targetable through synthetic lethality Current Treatment Paradigm Genetic Alterations in Cancer Next Generation Therapeutics Specifically targeting and disrupting genes essential for cancer cell survival SNIPRx identifies and targets necessary genes to induce synthetic lethality Hig

  5. Slide 5: Enabling target identification & patient insights through SNIPRx

    Enabling target identification & patient insights through SNIPRx® Predicted non-responders DRUG TARGET Small molecule inhibitor (clinical candidate) POTENTIAL SL DRUG TARGETS Viable VALIDATION NORMAL CELL CANCER-ASSOCIATED GENETIC LESION Predicted responders DRUG TARGET Viable Lethal SL genetic lesi

  6. Slide 6: Expanding pipeline of precision oncology therapeutics

    Expanding pipeline of precision oncology therapeutics PROGRAM TUMOR LESION DRUG TARGET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 RIGHTS Camonsertib (RP-3500/ RG6526) ATM + 16 STEP2 lesions ATR Lunresertib (RP-6306) CCNE1, FBXW7 + others PKMYT1 RP-1664 Undisclosed Undisclosed RP-3467 Polθ Inhibitor BRCA1/2

  7. Slide 7: Driving shareholder value through strategic collaborations

    Driving shareholder value through strategic collaborations Global development and commercialization collaboration for Camonsertib Multi-target discovery collaboration leveraging SNIPRx® discovery platform $135M upfront ~$1.2B potential milestones High single-digit to high-teens royalties 50/50 U.S.

  8. Slide 8: Proven experience in drug discovery and development

    Proven experience in drug discovery and development Leadership Team Scientific Founders Steve Forte, CPA Chief Financial Officer Michael Zinda, PhD Chief Scientific Officer Maria Koehler MD, PhD Chief Medical Officer Cameron Black, PhD Head of Discovery Philip Herman Chief Commercial, Portfolio Deve

  9. Slide 9: Lunresertib (RP-6306)

    Lunresertib — ; (RP-6306)

  10. Slide 10: Lunresertib: First-in-class, oral, small molecule, PKMYT1 inhibitor

    Lunresertib: First-in-class, oral, small molecule, PKMYT1 inhibitor Combination therapy achieved strong anti-tumor activity across multiple tumor types and tested genotypes; 33% overall response at preliminary RP2D (N=18) 50% RECIST response observed in camonsertib combination in largest cohort (gyn

  11. Slide 11: Lunresertib: The only clinical-stage therapeutic targeting PKMYT1

    Lunresertib: The only clinical-stage therapeutic targeting PKMYT1 Protein Kinase within the Wee1 kinase family Regulates cell cycle and is part of DNA damage repair-related signaling Inactivates CDK1 via phosphorylation of threonine14 (T14) holding the cell in S phase until ready to undergo mitosis

  12. Slide 12: ~90K patients across tumor types; ~65K among top tumors

    ~90K patients across tumor types; ~65K among top tumors CCNE1 amplification or inactivating mutations in FBXW7 and PPP2R1A Genetic alterations largely mutually exclusive Addressing unmet need in critical patient populations Top Tumors (New Advanced Cases, US+UK/EU4) Top Tumors (New Advanced Cases, U

  13. Slide 13: Evolving broad trial program: sponsored and collaborative

    Evolving broad trial program: sponsored and collaborative PPP2R1A FBXW7 Recurrent solid tumors Key inclusion criteria: CCNE1 amplification or inactivating mutations Determine RP2D dose / schedule Progress to late-stage trials MAGNETIC: + Gemcitabine MYTHIC: + Camonsertib MINOTAUR: + FOLFIRI IST: + C

  14. Slide 14: Lunresertib: MYTHIC Preliminary Phase Trial Results

    Lunresertib: MYTHIC Preliminary Phase 1 Trial Results (M1: Monotherapy) (M2: Camonsertib Combination Therapy) MONOTHERAPY Safe, well tolerated, and anti-tumor activity established (N=67) Recommended Phase 2 dose: 80 to 100mg twice daily in intermittent schedule CAMONSERTIB COMBINATION THERAPY Safe,

  15. Slide 15: Anti-tumor activity with lunresertib monotherapy

    Anti-tumor activity with lunresertib monotherapy FBXW7 PPP2R1A Baseline Left external iliac chain LN TA #1 – Week 6 Overall response: cPR (RECIST) RECIST target lesion decrease -41% Received therapy for 8.3 months Female 73 years old Metastatic recurrent uterine carcinosarcoma & One RECIST responder

  16. Slide 16: PKMYT1 and ATR inhibitors synergize to enhance anti-tumor activity

    PKMYT1 and ATR inhibitors synergize to enhance anti-tumor activity1 Lunresertib-sensitizing alterations engage ATR through replication stress Combination of ATR and PKMYT1 inhibition enhances CDK1 activation and premature mitosis 1ANE poster B057: Gallo et al. Preclinical development of PKMYT1 and A

  17. Slide 17: Responses to combination observed across tumor types and alterations

    Responses to combination observed across tumor types and lunresertib-sensitizing alterations * One response evaluable patient became uPR and four patients had responses confirmed after the Sept. 5, 2023 cutoff, data as of Oct. 6, 2023. Relevant patient tumor co-mutations †BRCA1 rearrangement and ‡BR

  18. Slide 18: Frequent and deep tumor reductions with lunre + cam combination

    *Efficacy evaluable patients only (≥1 post-baseline tumor assessment). Other tumor types include cervical (n=1), esophageal (n=1), GI (n=1), liver (n=1), lung (n=3), melanoma (n=1), osteosarcoma (n=1), pancreatic (n=2), and upper GI (n=1). CBR: overall response or time on treatment ≥ 16 wk w/o progr

  19. Slide 19: Most patients with gynecologic cancers had tumor reductions with combination treatment

    Most patients with gynecologic cancers had tumor reductions with combination treatment * Gynecologic cancers: ovarian, endometrial, and cervical cancers. Data represent the efficacy evaluable population (≥1 post-baseline tumor assessment). CBR, clinical benefit rate; OR, overall response based on RE

  20. Slide 20: Early response in recurrent FBXW7 mutated colorectal adenocarcinoma

    Early response in recurrent FBXW7 mutated colorectal adenocarcinoma FBXW7 Male 63 years old Recurrent colorectal adenocarcinoma Mutation Lunre 240mg QD 3/4 Cam 80mg QD 3/4 Overall response: cPR (RECIST) RECIST target lesion decrease -43.3% Received therapy for 27.6 weeks Left para-aortic lymph node

  21. Slide 21: Gradual response heralded by CA-125 decrease; recurrent CCNE1 amplified ovarian cancer

    Gradual response heralded by CA-125 decrease; recurrent CCNE1 amplified ovarian cancer Overall response: cPR (RECIST) RECIST target lesion decrease -70.2% Therapy ongoing for >21 weeks Female 56 years old High grade serous ovarian carcinoma Amplification RP2D: Lunre 80mg BID 3/4 Cam 80mg QD 3/4 CCNE

  22. Slide 22: Prompt response in recurrent cervical carcinosarcoma with a PPP2R1A mutation

    Prompt response in recurrent cervical carcinosarcoma with a PPP2R1A mutation Female 66 years old Recurrent cervical carcinosarcoma Mutation RP2D: Lunre 80mg BID 3/4 Cam 80mg QD 3/4 T01 Lymph node external iliac left PPP2R1A Baseline 6 weeks 12 weeks Tumor assessment CA-125 dynamics Overall response:

  23. Slide 23: Camonsertib (RP-3500 / RG6526)

    Camonsertib (RP-3500 / RG6526)

  24. Slide 24: Camonsertib: Potential best-in-class ATR inhibitor

    Camonsertib: Potential best-in-class ATR inhibitor Expanded potential with combination therapy Proof of concept established in Phase 1/2 monotherapy trial Durable antitumor activity in combination with PARP inhibitors and gemcitabine; meaningful clinical benefit in ovarian cancer Demonstrated synthe

  25. Slide 25: Potential across additional patient populations

    Potential across additional patient populations Top 10 Tumor Types* with Highest Prevalence of ATM Deficiency Top 10 Tumor Types* with Highest Prevalence of ATM Deficiency or STEP2 Genomic Alterations Source: *TCGA; Not weighted for tumor prevalence

  26. Slide 26: Expanding clinical development through Roche collaboration

    Expanding clinical development through Roche collaboration Note: Camonsertib monotherapy TRESR Module 2 expansion phase to be integrated into partnered clinical development plans under Roche IND Repare Trials Roche Collaboration TRESR Phase 1/2 Monotherapy (M1) + Talazoparib (M3) + Gemcitabine (M4)

  27. Slide 27: Camonsertib: TRESR & ATTACC Phase 1/2 Trial Results

    Camonsertib: TRESR & ATTACC Phase 1/2 Trial Results MONOTHERAPY Favorable safety profile (N=120) Proof-of-concept established in ovarian cancer 25% OR; 75% CBR; 8+ months PFS Clinical benefit in patients with BRCA1/2 mutations COMBINATION THERAPY Clinically meaningful anti-tumor activity in combinat

  28. Slide 28: Anti-tumor activity in ovarian cancer with monotherapy

    Anti-tumor activity in ovarian cancer with monotherapy *Platinum refractory/resistant: progression on platinum or a platinum-free interval of <6 mo. CBR: OR or ≥16w on therapy without progression 25% Overall response (5/20*) 35w Median PFS 75% Clinical benefit rate (CBR) 90% (18/20) patients had pri

  29. Slide 29: Clinically relevant benefit in patients with BRCA1/2 mutations with monotherapy

    Time on Treatment (wk) – BRCA1/BRCA2 Module 1 subjects with > 100mg/day dose levels Percent change from baseline in target lesions (BRCA1/BRCA2) Module 1 subjects > 100mg/day dose levels Clinically relevant benefit in patients with BRCA1/2 mutations with monotherapy CBR (OR or ≥16w on therapy withou

  30. Slide 30: Durable clinical benefit observed with combination therapy

    Durable clinical benefit observed with combination therapy Similar benefit observed in patients with platinum-resistant tumors (ORR 12%, CBR 49%) and non-platinum-resistant tumors (ORR 13%, CBR 46%) Benefit observed across multiple tumors, regardless of previous PARPi treatment 48% overall CBR (N=90

  31. Slide 31: Upcoming milestones

    Upcoming milestones 2H 2024 2H 2023 1H 2024 Camonsertib Phase 2 TAPISTRY trial initiation Lunresertib + carboplatin/paclitaxel combination Phase 1 IST initiation RP-1664 and RP-3467 (Polθi) focused investor event RP-1664 clinical trial initiation Initial lunresertib + FOLFIRI combination Phase 1 dat

  32. Slide 32: Developing Next-Generation Precision Oncology Therapeutics

    Developing Next-Generation Precision Oncology Therapeutics Differentiated and expanding clinical-stage pipeline Lunresertib: First-in class oral PKMYT1 inhibitor (Phase 1/2) Camonsertib: ATR inhibitor (Partnered with Roche) Additional near-term clinical programs Potential across multiple tumor types

  33. Slide 33: Insight that enriches. Precision that empowers.

    Insight that enriches. Precision that empowers. Corporate Presentation October 2023

Repare Therapeutics — Investor Presentation (October 2023) on 6ix